Adamas One Engages Adeptus Partners, LLC as Auditor of Record SCOTTSDALE, Ariz., Sept. 29, 2023 (GLOBE NEWSWIRE) — Adamas One Corp. (Nasdaq: JEWL) (“Adamas One,” “Adamas” or the “Company”), The Original Lab-Grown Diamond Company™, a high-tech company that leverages proprietary technology to produce high-quality, single-crystal, Lab-Grown Diamonds for jewelry and diamond materials for industrial uses,…

Semper Paratus Acquisition Corporation (Nasdaq: LGST, the “Company”) is making waves in the stock market once again! In a recent announcement, the company revealed that it has regained compliance with certain Nasdaq listing requirements. This news comes as a relief to investors and stakeholders who have been eagerly watching the company’s performance. It’s no secret…

Welcome to the Future of Cancer Treatment Onconova Therapeutics: Revolutionizing Patient Care It is with great excitement that Onconova Therapeutics, a leading biopharmaceutical company, has announced a groundbreaking development in the field of cancer treatment. The company’s latest research focuses on the use of rigosertib in patients with recessive dystrophic epidermolysis bullosa (RDEB) associated with…

The Federal Reserve’s latest interest rate decision Overview The Federal Reserve recently announced that they would be leaving interest rates unchanged, in line with market expectations. This decision comes as the economy has shown much stronger resilience than initially anticipated, leading to a revision of macroeconomic projections. Outlook The Dot Plot released by the Fed…

Bank of England Speakers Discuss Central Bank Liquidity Toolkit and Climate Change Bank of England’s Executive Director for Markets Andrew Hauser at Market News International Connect Event 05:30 US Eastern time (0930 GMT) at Chartered Accountants’ Hall Andrew Hauser, the Executive Director for Markets at the Bank of England, will be speaking at the Market…

ZyVersa Therapeutics CEO to Participate in BioFlorida Conference Panel Stephen C. Glover to Serve as Judge in BioPitch Competition ZyVersa’s Innovative Drug Candidates Mr. Stephen C. Glover, the CEO of ZyVersa Therapeutics, will be taking part in a panel discussion at the upcoming BioFlorida Conference. This conference will provide a platform for life science companies…